Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System

Laura Semenzato1*, Jérémie Botton1, Bérangère Baricault1, Jacqueline Deloumeaux2, Clarisse Joachim3, Emmanuelle Sylvestre4, Rosemary Dray-Spira1, Alain Weill1, Mahmoud Zureik1

1 EPI-PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products—ANSM, French National Health Insurance—CNAM), Saint-Denis, France, 2 Clinical Research and Innovation Department, Guadeloupe University Hospital Center, Les Abymes, Guadeloupe, 3 Martinique General Cancer Registry, Cancerology Hematology Urology Center from Martinique University Hospital Center, Fort-de-France, Martinique, 4 Clinical Data center—Martinique University Hospital Center, Fort-de-France, Martinique

* laura.semenzato@assurance-maladie.fr

Abstract

Importance
Although several observational studies on the effectiveness of SARS-CoV-2 vaccination have been published, vaccination coverage by August, 3 2021, remained low in the French overseas territories, despite Martinique and Guadeloupe experiencing an unprecedented number of COVID-19-related hospitalizations. We aimed to determine the association between COVID-19 vaccination and severe COVID-19 in the French overseas territories.

Methods
The French National Health Data System was used to conduct a 1:1 matched-cohort study. For each individual receiving a first dose of BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, or Ad26.COV2-S vaccine between December 27, 2020, and July 31, 2021, one unvaccinated individual was randomly selected and matched for year of birth, sex, and overseas territories on the date of vaccination. We estimated vaccine effectiveness against COVID-19-related hospitalization and in-hospital death after a full vaccination schedule, defined as ≥14 days after the second dose. Analyses were stratified according to the number of comorbidities.

Results
276,778 vaccinated individuals had a double-dose vaccination during the follow-up period and were followed with their paired unvaccinated control. The average age was 50 years and 53% were women. During a median 77 days of follow-up from day 14 after the second
injection, 96 COVID-19-related hospitalizations occurred among vaccinated individuals and 1,465 among their unvaccinated counterparts. Overall, vaccine effectiveness against hospitalization was 94% (95%CI [93–95]) and exceeded 90% in each overseas territory, except Mayotte. The results were similar looking specifically at hospitalizations between July 15 and September 30, 2021. Vaccine effectiveness against in-hospital death was similar (94% [95%CI 91–96]). The risk of COVID-19-related hospitalization increased with the number of comorbidities, especially among vaccinated individuals.

Conclusions and relevance

In conclusion, vaccination has a major effect in reducing the risk of severe Covid-19 in the French overseas territories. The risk of COVID-19-hospitalization was very low among vaccinated individuals, especially in the absence of comorbidities. These results aim to increase confidence in vaccine effectiveness in overseas territories in hope of achieving better vaccination coverage.

Introduction

Vaccine efficacy [1–4] in clinical trials against symptomatic COVID-19 has ranged from 70 to 95% and real-world effectiveness of the mRNA and ChAdOx1 nCoV-19 vaccines [5–12] against COVID-19 hospitalization was estimated to be approximately 90%. In France, where 66.6 million people reside in mainland France and 2.2 million in French overseas territories, the vaccination campaign began on December 27, 2020, and was extended to all adults in mid-May 2021 and to children aged 12 and older in mid-June. However, vaccination coverage by August 3, 2021 remained low in the French overseas territories: approximately 43% of patients had received at least one injection in Reunion (Indian Ocean) and 20–25% in Mayotte (Indian Ocean) and the overseas territories in the Caribbean (Martinique, Guadeloupe) and South America (French Guiana) versus 65% in mainland France [13]. Moreover, viral circulation differed between mainland France and the French overseas territories. In mainland France in 2021, a high number of COVID-19-related hospitalizations were first observed in March and April, followed by a lower increase of cases in July and August, in the context of high vaccination coverage. Martinique and Guadeloupe and, to a lesser extent Reunion and French Guiana, experienced an unprecedented number of COVID-19-related hospitalizations since the beginning of the epidemic between mid-July and the end of September 2021, related to the emergence of the Delta variant. We estimated vaccine effectiveness against severe COVID-19 in the French overseas territories over a period including that of high viral circulation.

Materials and methods

We used the French National Health Data System (Système National des Données de Santé, SNDS) to conduct a 1:1 matched-cohort study (more details in the eMethods in S1 File). For each individual receiving a first dose of one of the first vaccines authorized in France (i.e., BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, or Ad26.COV2.S) between December 27, 2020, and July 31, 2021, one unvaccinated control matched for year of birth, sex, and overseas territories, was randomly selected on the date of vaccination (first injection). If a control subject was vaccinated during follow-up, follow-up was stopped for the pair, and the subject was then eligible to be included as a vaccinated subject. We chose not to exclude the few patients
vaccinated with the Ad26.COV2.S vaccine whose vaccination schedule was first in a single
injection before requiring a booster dose from late summer. We estimated vaccine effective-
ness after a full vaccination schedule, defined as ≥14 days after the second dose, as the per-
centage of risk reduction (1-Hazard Ratio) in COVID-19-related hospitalization and in-hospital
COVID-19-related death using Cox proportional hazards models adjusted for the 7 sociode-
mographic characteristics, history of COVID-19 and the 23 comorbidities. Each subject was
followed until COVID-19-related hospitalization, death, or the end of follow-up on September
30, 2021. If one individual of a matched pair died or had an event of interest, the other individ-
ual was not censored. Additional pair-censoring analyses on death or event of at least one indi-
vidual in the matched pair were performed in S1 Table. We performed sensitivity analyses:
first, we focused on events occurring over a period where the delta variant was predominant,
from July 15 2021, to September 30, 2021, by excluding pairs with at least one individual hospi-
talized before July 15, 2021. Then, we excluded pairs with at least one individual having
COVID-19 history (S2 Table). We also investigated effectiveness according to the number of
comorbidities, defined as a categorical variable ranging from 0–5 or more, based on the sum of
47 identified chronic conditions (S3 Table) [14].

Ethic statement
The research group has permanent regulatory access to the data from the French National
Health Data System (French decree No. 2016–1871 of December 26, 2016, on the processing
of personal data called National Health Data System and French law articles Art. R. 1461–13
and 14) upon authorization from the French Data Protection Office (CNIL Commission Nationale
de l'Informatique et des Libertés). No informed consent was required because the data are
anonymized.

Results and discussion
In total, 276,778 individuals (97.8% [n = 270,641] with the BNT162b2, 0.9% [n = 2,581] with
the mRNA-1273, 1.3% [n = 3,505] with the ChAdOx1 nCoV-19, and 0.0% [n = 8] with the
Ad26.COV2.S vaccine) had a double-dose vaccination during the follow-up period (patients
‘distribution by month of 2nd injection in S4 Table) and were followed with their unvaccinated
counterparts. Supplementary analysis restricted to BNT162b2 2-doses-vaccinated individuals
during the follow-up period showed no difference in outcome (S5 Table). Among vaccinated
individuals, 46,221 lived in Guadeloupe, 43,264 in Martinique, 26,328 in French Guiana,
149,683 in Reunion, and 11,282 in Mayotte. They were, on average, 50 years old and 53% were
women (Table 1). The two groups were relatively similar in terms of health characteristics.
During a median follow-up of 77 days (interquartile range, 42–111) from day 14 after the
second injection, 96 COVID-19-related hospitalizations occurred among vaccinated and 1,465
among unvaccinated individuals. 45% and 40% respectively had a SARS-COV-2 positive test,
which occurred on average 5 days before hospitalization. Overall vaccine effectiveness against
hospitalization was estimated to be 94% (95%CI [93–95]). It exceeded 90% in each overseas
territory, except Mayotte, where it was 78% (Table 2). Vaccine effectiveness against in-hospital
death was similar when adjusting for all the variables (Table 2) or when restricting to a few
ones (S6 Table): 94% (95%CI [91–96]), with 19 deaths among vaccinated and 285 among
unvaccinated individuals. Similar results were also obtained when restricting the study period
from July 15 2021, to September 30, 2021, only (Table 3) or when excluding pairs with at least
one individual having COVID-19 history (S2 Table).

Among hospitalized patients, 26% of those vaccinated had at least five comorbidities versus
only 7% among unvaccinated patients. COVID-19-related hospitalizations increased with the
Table 1. Characteristics of the study population with double-dose vaccination and their paired unvaccinated individuals.

| Baseline characteristics          | No vaccine (n = 276,778) | Vaccine (n = 276,778) | Standardized differences |
|-----------------------------------|--------------------------|-----------------------|--------------------------|
| Age (year) Mean (SD)              | 49.81 (18.88)            | 49.81 (18.88)         | 0.00000                  |
| Age                               |                          |                       |                          |
| -20                               | 19,610 (7.1)             | 19,610 (7.1)          |                          |
| 20–29                             | 27,665 (10.0)            | 27,665 (10.0)         |                          |
| 30–39                             | 37,412 (13.5)            | 37,412 (13.5)         |                          |
| 40–49                             | 46,048 (16.6)            | 46,048 (16.6)         |                          |
| 50–54                             | 27,207 (9.8)             | 27,207 (9.8)          |                          |
| 55–59                             | 28,507 (10.3)            | 28,507 (10.3)         |                          |
| 60–64                             | 25,036 (9.0)             | 25,036 (9.0)          |                          |
| 65–69                             | 21,864 (7.9)             | 21,864 (7.9)          |                          |
| 70–74                             | 16,555 (6.0)             | 16,555 (6.0)          |                          |
| 75–79                             | 11,774 (4.3)             | 11,774 (4.3)          |                          |
| 80–84                             | 7,875 (2.8)              | 7,875 (2.8)           |                          |
| 85–89                             | 4,645 (1.7)              | 4,645 (1.7)           |                          |
| 90+                               | 2,580 (0.9)              | 2,580 (0.9)           |                          |
| Sex                               |                          |                       |                          |
| Women                             | 147,452 (53.3)           | 147,452 (53.3)        | 0.00000                  |
| Men                               | 129,326 (46.7)           | 129,326 (46.7)        |                          |
| Administrative regions            |                          |                       |                          |
| Guadeloupe                        | 46,221 (16.7)            | 46,221 (16.7)         | 0.00000                  |
| French Guiana                     | 26,328 (9.5)             | 26,328 (9.5)          |                          |
| Reunion Island                    | 149,683 (54.1)           | 149,683 (54.1)        |                          |
| Martinique                        | 43,264 (15.6)            | 43,264 (15.6)         |                          |
| Mayotte                           | 11,282 (4.1)             | 11,282 (4.1)          |                          |
| Flu vaccination in 2018 or 2019    |                          |                       |                          |
| No                                | 274,147 (99.0)           | 269,355 (97.3)        | 0.12992                  |
| Yes                               | 2,631 (1.0)              | 7,423 (2.7)           |                          |
| Frailty                           |                          |                       |                          |
| No                                | 257,031 (92.9)           | 261,338 (94.4)        | -0.06381                 |
| Yes                               | 19,747 (7.1)             | 15,440 (5.6)          |                          |
| Alcoholism                        |                          |                       |                          |
| No                                | 272,853 (98.6)           | 273,974 (99.0)        | -0.03697                 |
| Yes                               | 3,925 (1.4)              | 2,804 (1.0)           |                          |
| Smoking                           |                          |                       |                          |
| No                                | 270,945 (97.9)           | 268,593 (97.0)        | 0.05411                  |
| Yes                               | 5,833 (2.1)              | 8,185 (3.0)           |                          |
| Hypertension                      |                          |                       |                          |
| No                                | 216,952 (78.4)           | 209,894 (75.8)        | 0.06073                  |
| Yes                               | 59,826 (21.6)            | 66,884 (24.2)         |                          |
| Diabetes                          |                          |                       |                          |
| No                                | 244,852 (88.5)           | 242,626 (87.7)        | 0.02481                  |
| Yes                               | 31,926 (11.5)            | 34,152 (12.3)         |                          |
| Dyslipidemia                      |                          |                       |                          |
| No                                | 253,739 (91.7)           | 245,879 (88.8)        | 0.09587                  |
| Yes                               | 23,039 (8.3)             | 30,899 (11.2)         |                          |
| Coronary diseases                 |                          |                       |                          |
| No                                | 271,250 (98.0)           | 269,569 (97.4)        | 0.04052                  |
| Yes                               | 5,528 (2.0)              | 7,209 (2.6)           |                          |
| Heart failure                     |                          |                       |                          |
| No                                | 273,728 (98.9)           | 274,117 (99.0)        | -0.01391                 |
| Yes                               | 3,050 (1.1)              | 2,661 (1.0)           |                          |
| Cardiac rhythm or conduction disturbances |            |                       |                          |
| No                                | 272,811 (98.6)           | 272,457 (98.4)        | 0.01053                  |
| Yes                               | 3,967 (1.4)              | 4,321 (1.6)           |                          |
| Valvular diseases                 |                          |                       |                          |
| No                                | 274,927 (99.3)           | 274,718 (99.3)        | 0.00902                  |
| Yes                               | 1,851 (0.7)              | 2,060 (0.7)           |                          |
| Obliterating arterial disease of the lower limbs |       |                       |                          |
| No                                | 274,167 (99.1)           | 274,064 (99.0)        | 0.00381                  |
| Yes                               | 2,611 (0.9)              | 2,714 (1.0)           |                          |
| Stroke                            |                          |                       |                          |
| No                                | 271,155 (98.0)           | 272,111 (98.3)        | -0.02557                 |
| (Continued)                       |                          |                       |                          |
number of comorbidities, especially among vaccinated individuals (compared to patients without comorbidity, aHR 29.5 95%CI [13.4–64.9] among vaccinated with 5+ comorbidities and aHR 4.4 95%CI [3.5–5.6] among unvaccinated individuals with 5+ comorbidities) (Table 4).

Vaccines were all the more effective among individuals with no or few comorbidities (VE of 97% [95%; 98%] among individuals with no comorbidity vs 83% [73%; 89%] among 5+) (Table 5).

Vaccines were highly effective against severe COVID-19 in the French overseas territories, as observed in mainland France. The lower effectiveness observed in Mayotte is likely related to the low number of events due to low viral circulation in Mayotte during this period, leading
to a much higher uncertainty for the estimates. The vaccine effectiveness appeared to persist during the strong epidemic of the Delta variant, which particularly affected Martinique and Guadeloupe, between mid-July and the end of September 2021, with more than 2,700 and 2,000 patients hospitalized for COVID-19, respectively, and the number of COVID-19 hospital deaths corresponding to 75% and 60%, respectively, of all COVID-19 hospital deaths registered in each of these territories between the beginning of the epidemic and the end of December 2021.

The overseas territories benefit from the mandatory French National Health system in the same way as mainland France. Despite the availability of vaccine doses within the same timeframe as in mainland France, utilization rates of doses delivered to overseas territories remained low. Such low vaccination coverage has been associated with a distrust in public
authority related to complex and multifactorial issues [15], including the management of chlordecone use, a persistent organochlorine pesticide, prohibited in the US since 1976, in France since 1990, and since 1993 in the French West Indies. Low vaccination rates have also been observed in Montserrat and the British Virgin Islands, British overseas territories also located in the Caribbean. However, other overseas territories benefit from high vaccination coverage, such as most of the British Overseas Territories, with some of the highest global vaccination rates [16], or Puerto Rico since the decision of strict vaccine mandates guided by accurate scientific results in the real world on its population [17].

The stronger association among 2-doses-vaccinated individuals between the residual risk of COVID-19-related hospitalization and the number of comorbidities should not be interpreted as vaccine failures. Vaccines were highly effective, but even more so among those with no or few comorbidities (Table 5). This is of particular interest, as people from the French overseas territories have higher frequencies of diabetes, chronic dialysis, and stroke than in mainland France [18], which are medical risk factors for the development of severe COVID-19 [14].

### Table 3. Vaccine effectiveness measured as overall reduction of the risk of Covid-19-related in-hospital death from day 14 after the 2nd injection for hospitalizations from July 15 to September 30, 2021, only. Hazard ratio (HRs) were obtained using Cox models taking into account all the variables described in Table 1.

| Region      | Vaccine exposition | Number of subjects | Number of event (%) | Median follow-up [interquartile range] | Crude HR (95% CI) | Adjusted HR (95% CI) | Vaccine effectiveness |
|-------------|--------------------|--------------------|---------------------|----------------------------------------|-------------------|-----------------------|-----------------------|
| Overseas territories | no | 276,778 | 1,206 (0.44%) | 78 [42–111] | 1 (1) | 1 (1) | 94% (93%; 95%) |
|              | yes | 276,778 | 79 (0.03%) | 78 [42–111] | 0.07 (0.05–0.08) | 0.06 (0.05–0.07) | 94% (93%; 95%) |
| Guadeloupe  | no | 46,221 | 375 (0.82%) | 87 [54–120] | 1 (1) | 1 (1) | - |
|              | yes | 46,221 | 43 (0.09%) | 87.5 [54–120] | 0.11 (0.08–0.16) | 0.09 (0.07–0.13) | 91% (87%; 93%) |
| Martinique  | no | 43,264 | 462 (1.07%) | 94 [48–129] | 1 (1) | 1 (1) | - |
|              | yes | 43,264 | 23 (0.05%) | 95 [49–129] | 0.05 (0.03–0.08) | 0.05 (0.03–0.07) | 95% (93%; 97%) |
| French Guiana | no | 26,328 | 75 (0.29%) | 100 [63–129] | 1 (1) | 1 (1) | - |
|              | yes | 26,328 | 2 (0.01%) | 100 [63–129] | 0.03 (0.01–0.11) | 0.03 (0.01–0.11) | 97% (89%; 99%) |
| Reunion Island | no | 149,683 | 289 (0.2%) | 68 [38–97] | 1 (1) | 1 (1) | - |
|              | yes | 149,683 | 9 (0.01%) | 68 [38–97] | 0.03 (0.02–0.06) | 0.03 (0.01–0.06) | 97% (94%; 99%) |
| Mayotte     | no | 11,282 | 5 (0.05%) | 79 [44–119] | 1 (1) | 1 (1) | - |
|              | yes | 11,282 | 2 (0.02%) | 79 [44–119] | 0.40 (0.08–2.06) | 0.36 (0.07–1.92) | 64% (-92%; 93%) |

Table 4. Distribution, hazard ratios (HRs), and 95% confidence intervals (95%CIs) for COVID-19-related hospitalization and in-hospital mortality according to exposure and the number of comorbidities.

| Number of comorbidities | Number of events | Model adjusted for age and sex only | Multivariable model |
|-------------------------|------------------|-------------------------------------|---------------------|
|                         | Vaccinated       | Unvaccinated                        | Vaccinated          | Unvaccinated          | Vaccinated | Unvaccinated          |
| 0                       | 168,704 61%      | 181,083 65%                         | 12 13%              | 458 31%               | 1          | 1.465                  | 1.86 (1.06–3.29)      |
| 1                       | 50,546 18%       | 46,258 17%                          | 11 11%              | 309 21%               | 1          | 1.625                  | 2.43 (1.42–4.11)      |
| 2                       | 26,411 10%       | 23,202 8%                           | 18 19%              | 261 18%               | 1          | 1.465                  | 2.43 (1.42–4.11)      |
| 3                       | 17,447 6%        | 14,627 5%                           | 15 16%              | 224 15%               | 1          | 1.465                  | 2.43 (1.42–4.11)      |
| 4                       | 8,153 3%         | 6,818 2%                            | 15 16%              | 107 7%                | 1          | 1.465                  | 2.43 (1.42–4.11)      |
| 5 or more               | 5,517 2%         | 4,790 2%                            | 25 26%              | 106 7%                | 1          | 1.465                  | 2.43 (1.42–4.11)      |
Although vaccination coverage has improved in the French overseas territories, it remains much lower than in mainland France: in mid-February 2022, more than 78% of the mainland French population had received at least one injection and 57% had had a booster injection versus 51% and 24%, respectively, in the overseas territories.

The SNDS is a comprehensive claims database that allowed us to analyse vaccine effectiveness for individuals from the whole population of the French overseas territories benefiting from a 2-dose vaccination schedule, thus limiting selection bias. We focused on patients requiring admission specifically for SARS-CoV-2 infection, and due to the invoicing nature of the codifications recorded by public and private healthcare establishments, diagnostic coding errors are likely to be rare. Given the predominance of the Delta variant over the period analyzed, our estimates may not apply to periods of high circulation of other variants, such as Omicron. We may have a misclassification bias due to differential health care seeking behavior between vaccinated individuals and unvaccinated controls. This may lead to a potential underestimation of illness among unvaccinated individuals and then an underestimation of vaccine effectiveness. Health care seeking behavior may also be considered as a confounding factor: people with less use of healthcare would be less vaccinated and hospitalized for covid-19. However, this would have a limited impact due to the severity of the endpoint, and would then lead to an underestimation of vaccine effectiveness. Our study may also have been affected by other residual confounding due to differences between vaccinated individuals and unvaccinated controls after matching and adjustment for a high range of comorbidities that were shown to be associated with COVID-19-related hospitalization.

In conclusion, vaccines had a major effect in reducing COVID-19-related hospitalizations in the French overseas territories. The risk of COVID-19-hospitalization was very low among vaccinated individuals, especially in the absence of comorbidities. Achieving better vaccination coverage in overseas territories would limit the incidence of severe COVID-19.

Table 5. Vaccine effectiveness measured as overall reduction of the risk of Covid-19-related hospitalization from day 14 after the 2nd injection stratified by the number of comorbidities.

| Criteria | Number of comorbidities | Vaccine exposition | Number of subjects | Number of event (%) | Median follow-up [interquartile range] | Crude HR (95% CI) | Adjusted HR (95% CI) | Vaccine effectiveness |
|----------|--------------------------|--------------------|--------------------|---------------------|---------------------------------------|------------------|----------------------|----------------------|
| Hospitalization | 0 | no | 181083 | 458 (0.25%) | 70 [40–102] | 1 | 1 | 97% (95%; 98%) |
| | | yes | 168704 | 12 (0.01%) | 68 [38–99] | 0.03 (0.02–0.05) | 0.03 (0.02–0.05) | 97% (95%; 98%) |
| | 1 | no | 46258 | 309 (0.67%) | 85 [48–118] | 1 | 1 | - |
| | yes | 50546 | 11 (0.02%) | 85 [48–119] | 0.03 (0.02–0.06) | 0.03 (0.02–0.06) | 97% (94%; 98%) |
| | 2 | no | 23202 | 261 (1.12%) | 91 [54–125] | 1 | 1 | - |
| | yes | 26411 | 18 (0.07%) | 94 [57–127] | 0.06 (0.04–0.10) | 0.06 (0.04–0.10) | 94% (90%; 96%) |
| | 3 | no | 14627 | 224 (1.53%) | 95 [57–129] | 1 | 1 | - |
| | yes | 17447 | 15 (0.09%) | 98 [62–132] | 0.06 (0.03–0.09) | 0.05 (0.03–0.09) | 95% (91%; 97%) |
| | 4 | no | 6818 | 107 (1.57%) | 97 [58–132] | 1 | 1 | - |
| | yes | 8153 | 15 (0.18%) | 101 [66–140] | 0.11 (0.06–0.19) | 0.10 (0.05–0.17) | 90% (83%; 95%) |
| | 5 or more | no | 4790 | 106 (2.21%) | 99 [61–134] | 1 | 1 | - |
| | yes | 5517 | 25 (0.45%) | 106 [70–143] | 0.18 (0.12–0.28) | 0.17 (0.11–0.27) | 83% (73%; 89%) |

https://doi.org/10.1371/journal.pone.0274309.t005
Supporting information

S1 Table. Vaccine effectiveness against COVID-19-related hospitalisation depending on censoring variable.
(DOCX)

S2 Table. Vaccine effectiveness measured as overall reduction of the risk of Covid-19-related hospitalization from day 14 after the 2nd injection for individuals without COVID-19 history. Hazard ratios (HRs) were obtained using Cox models taking into account all the variables described in Table 1.
(DOCX)

S3 Table. Algorithms for identification of chronic conditions.
(DOCX)

S4 Table. Patients' distribution by month of 2nd injection.
(DOCX)

S5 Table. Vaccine effectiveness measured as overall reduction of the risk of Covid-19-related hospitalization from day 14 after the 2nd injection for individuals fully vaccinated with the BNT162b2 vaccine. Hazard ratios (HRs) were obtained using Cox models taking into account all the variables described in Table 1.
(DOCX)

S6 Table. Vaccine effectiveness measured as overall reduction of the risk of Covid-19-related and in-hospital death from day 14 after the 2nd injection. Hazard ratios (HRs) were obtained using Cox models taking into account age (<75 vs ≥75), gender, combining alcoholism and smoking, frailty and number of comorbidity.
(DOCX)

S1 File.
(DOCX)

Author Contributions

Conceptualization: Laura Semenzato, Jérémie Botton, Bérangère Baricault, Rosemary Dray-Spira, Alain Weill, Mahmoud Zureik.

Data curation: Laura Semenzato.

Formal analysis: Laura Semenzato.

Methodology: Laura Semenzato, Jérémie Botton.

Supervision: Rosemary Dray-Spira, Alain Weill, Mahmoud Zureik.

Writing – original draft: Laura Semenzato.

Writing – review & editing: Jérémie Botton, Jacqueline Deloumeaux, Clarisse Joachim, Emmanuelle Sylvestre, Rosemary Dray-Spira, Alain Weill, Mahmoud Zureik.

References

1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383:2603–15. https://doi.org/10.1056/NEJMoai2034577 PMID: 33301246
2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384:403–16. https://doi.org/10.1056/NEJMoa2035389 PMID: 33378609

3. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet 2020; 396:1979–93. https://doi.org/10.1016/S0140-6736(20)32466-1 PMID: 33228855

4. Voysey M, ClemenS SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 2021; 397:99–111. https://doi.org/10.1016/S0140-6736(21)00947-8 PMID: 33306989

5. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet 2021; 397:1819–29. https://doi.org/10.1016/S0140-6736(21)00947-8 PMID: 33964222

6. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med 2021; 385:1355–71. https://doi.org/10.1056/NEJMoa2110362 PMID: 34496194

7. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. The Lancet 2021; 398:1407–16. https://doi.org/10.1016/S0140-6736(21)02183-8 PMID: 34619098

8. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med 2021; 385:187–9. https://doi.org/10.1056/NEJMmc2104974 PMID: 33951357

9. Jabagi Marie Joëlle Botton Jérémie, Baricault Bérangère Bouillon Kim, Marion Bertrand, Laura Semenzato, et al. Estimation de l’impact de la vaccination chez les personnes âgées de 50–74 ans sur le risque de formes graves de Covid-19 en France à partir des données du Système National des Données de Santé (SNDS) n.d.:32.

10. Bouillon K, Baricault B, Botton J, Jabagi M-J, Bertrand M, Semenzato L, et al. Estimation de l’impact de la vaccination chez les personnes âgées de 75 ans et plus sur le risque de formes graves de Covid-19 en France à partir des données du Système National des Données de Santé (SNDS)—actualisation jusqu’au 20 juillet 202d.n.d.:33.

11. Botton J, Dray-Spira R, Baricault B, Drouin J, Bertrand M, Jabagi M-J, et al. Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines. Vaccine 2022; 40:414–7. https://doi.org/10.1016/j.vaccine.2021.12.009 PMID: 34924220

12. Botton J, Semenzato L, Jabagi M-J, Baricault B, Weill A, Dray-Spira R, et al. Effectiveness of Ad26. COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations. JAMA Netw Open 2022; 5: e220868. https://doi.org/10.1001/jama networkopen.2022.0868 PMID: 35234883

13. Tristan Gaudiaut. L’avancée de la vaccination selon les régions 2021. https://fr.statista.com/infographie/25341/taux-de-vaccination-par-region-en-france/.

14. Semenzato L, Botton J, Drouin J, Cuencot F, Dray-Spira R, Weill A, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. The Lancet Regional Health—Europe 2021; 8:100158. https://doi.org/10.1016/j.lanepe.2021.100158 PMID: 34308411

15. Mulot Stéphanie. Sur le refus de la vaccination contre le Covid-19 en Guadeloupe. AOC Media 2021;19.

16. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav 2021; 5:947–53. https://doi.org/10.1038/s41562-021-01122-8 PMID: 33972767

17. Robles-Fontán MM, Nieves EG, Cardona-Gerena I, Irizarry RA. Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico. The Lancet Regional Health—Americas 2022; 9:100212. https://doi.org/10.1016/j.lanare.2022.100212 PMID: 35229081

18. Filipovic-Piucci A, Rigault A, Fagot-Campagna A, Tuppip P. L’état de santé des populations des départements d’outre-mer en 2012, comparativement à la métropole: une analyse de la base nationale de l’Assurance maladie. Revue d’Épidémiologie et de Santé Publique 2016; 64:175–83. https://doi.org/10.1016/j.respe.2016.01.099 PMID: 27238162